Could an antibody boost chemo for tough blood cancers?
NCT ID NCT07072585
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This large clinical trial is testing whether adding the drug daratumumab to standard chemotherapy helps children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL). Daratumumab is an antibody that targets a protein on cancer cells, helping the immune system attack them. The study will compare event-free survival between those who get chemo alone and those who get chemo plus daratumumab.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Daratumumab (a monoclonal antibody) added to standard chemotherapy
What this could lead to
If successful, this could lead to a more effective first-line treatment for T-ALL and T-LL, potentially improving long-term survival rates.
What could go wrong
This is a large but still experimental trial. Daratumumab may not improve outcomes over chemotherapy alone, and side effects from adding it could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.